Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB) -- Ignore unavailable to you. Want to Upgrade?

To: Heat Shock who wrote (132)	8/2/2000 6:33:48 PM
From: Heat Shock	Read Replies (1) \| Respond to of 236

To all: William Marsh made a good post over at stockhouse.ca about an email he got from StressGen IR. Here is part of it: The two attachments she sent me were press releases. One is posted in STOCKHOUSE , the other I had not seen before. Here is a quote from the one which was new to me. These documents came with revisions marked (in WORD). I will try to paste them in as received - in general it is intelligible: At 3 study sites, Aa randomized, double-blinddouble blind, placebo-controlled trial (SGN-00101-9901) of 3 monthly subcutaneous doses of HspE7, 100 g, was conducted in patients with biopsy-proven anal anal dysplasia classified as high grade anal dysplasiasquamous intraepithelial lesions (HGSIL). Patients failing to achieve a downgrade of pathological dysplasia to low grade SILwith persistent HSIL (LGSIL) in all biopsy or cytological specimens taken after three months1 month after completing 3 injections were permitted to cross over to an open label trial (9902) of 3 additional doses of HspE7, 500 g. . TThe first 8 consecutive patients in this cross- over study were enrolled at a single site, and . tThis report represents the investigator’s analysis of the course of these patients.. Seven men and 1 woman crossed to 9902 and received treatment at 500 *g x3. After 3 injections of HspE7, Aall 8 patients had evidence of clinical response determined colposcopically, and the physician’s global assessment of clinical benefit improved by 65% to 95%. quantified as a downgrading in the appropriate surgical procedure needed to completely to clear anogenital dysplasia.For all 8, the surgical procedure that would have been recommended for clearance of lesions became less extensive and/or less invasive. At baseline, 5/8 would have required surgery under general anesthesia and 3/8 would have required an office procedure ablation such as laser surgery. After treatment, 1/8 would have required no procedure and 5/8 would have required topical treatment; only one still would have required surgery under general anesthesia but asand that, a much less extensive procedure. The physician’s global assessment of clinical benefit improved in all eight by 65% to 95%. Serial biopsies were taken from all patients. Baseline showed HGSIL in all 8. One Three months after the third injection,initiation of treatment, dysplasia was improved in all patients: 1 had no dysplasia, 2 had low grade (LGSIL), and 5 had focal moderate, less extensive (focal) and or less severe dysplasia than at baseline. These preliminary data suggest that HspE7 is active in anal dysplasia. Further follow up at the 6-month observation point may reveal additional improvement without additional treatment. A phase III randomized, double blind, placebo-controlled study (SGN-00101-0001) is planned to reproduce these observations in rigorous fashion. stockhouse.ca Thanks, William. Heat.